Daclizumab Hematologic Response 3 months [clinicaltrials_resource:0a4a3a45d6ecb4685aadcf92a9b02d40]
Daclizumab, 1 mg/kg of body weight, will be given for a total of 5 intravenous infusions to subjects diagnosed with moderate aplastic anemia (MAA), pure red cell aplasia (PRCA), Diamond Blackfan anemia (DBA), relapse and refractory severe aplastic anemia (SAA) will receive treatment. The Diamond Blackfan anemia arm was closed due to the lack of accrual. The hematologic response will be evaluated at 3 months.
A complete hematologic response will be considered an achievement of normal blood counts. A partial response was defined as any response less than a complete response. The primary endpoint was a hematologic response in at least one affected peripheral blood count parameter, as determined by 3 separate measurements in the first 12 weeks after completion of the infusion.
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Daclizumab Hematologic Response 3 months [clinicaltrials_resource:0a4a3a45d6ecb4685aadcf92a9b02d40]
Daclizumab, 1 mg/kg of body weight, will be given for a total of 5 intravenous infusions to subjects diagnosed with moderate aplastic anemia (MAA), pure red cell aplasia (PRCA), Diamond Blackfan anemia (DBA), relapse and refractory severe aplastic anemia (SAA) will receive treatment. The Diamond Blackfan anemia arm was closed due to the lack of accrual. The hematologic response will be evaluated at 3 months.
A complete hematologic response will be considered an achievement of normal blood counts. A partial response was defined as any response less than a complete response. The primary endpoint was a hematologic response in at least one affected peripheral blood count parameter, as determined by 3 separate measurements in the first 12 weeks after completion of the infusion.
Bio2RDF identifier
0a4a3a45d6ecb4685aadcf92a9b02d40
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:0a4a3a45d6ecb4685aadcf92a9b02d40
measure [clinicaltrials_vocabulary:measure]
Daclizumab Hematologic Response
time frame [clinicaltrials_vocabulary:time-frame]
description
Daclizumab, 1 mg/kg of body we ...... er completion of the infusion.
identifier
clinicaltrials_resource:0a4a3a45d6ecb4685aadcf92a9b02d40
title
Daclizumab Hematologic Response 3 months
@en
type
label
Daclizumab Hematologic Respons ...... a3a45d6ecb4685aadcf92a9b02d40]
@en